Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:

Therapeutic Areas/Disease States:

Non-Small Cell Lung Cancer (adenocarcinoma)

Intended Audience: Oncologists, Pulmonologists, Surgeons, Pathologists, Community HCPs; Patients/Caregivers

Bayer TA Rationale for Educational Support:

Areas of interest based on referenced literature:

• Treatment and management of non-small cell lung cancer (adenocarcinoma)
  • Role of biomarkers in treatment of the patient with non-small cell lung cancer (adenocarcinoma)
  • Education on biomarker driven testing strategies/appropriate testing modalities
• Role of TRK-fusion and impact of TRK-fusion testing in non-small lung cancer (adenocarcinoma) treatment algorithms
  • Implication of TRK pathway aberrations in the pathogenesis of cancer
• Treatment and management of TRK fusion cancers
  • Understanding of efficacy and safety profiles of approved TRK inhibitors
  • How to Prioritize Treatment
• Multi-disciplinary approach to precision medicine & importance of precision medicine in community regional settings

Proposal Requirements:

All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning objectives
• Proposed faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan (required on a quarterly basis)
• Detailed budget 

Provider Justification:

• Copy of most recent accreditation letter and status
• Sample of other program(s) in similar therapeutic areas

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

Management and treatment of metastatic NSCLC

1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 4.2025 – May 23, 2025. (Link)

Diagnosis of TRK fusion cancer

1. Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58-66. (Link)
2. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731-47. (Link)
3. Halliday PR, Blakely CM, Bivona TG. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Curr Oncol Rep. 2019;21(3):21. (Link)
4. Wong D, Yip S, Sorensen PH. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. Pathol Oncol Res. 2020;26(3):1385-99. (Link)
5. Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38-46. (Link)
6. Klink AJ, Kavati A, Gassama A, Kozlek T, Gajra A, Antoine R. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists. Target Oncol. 2022;17(5):549-61. (Link)
7. Yang AT, Laetsch TW. Safety of current treatment options for NTRK fusion-positive cancers. Expert Opin Drug Saf. 2023;22(11):1073-89. (Link)
8. Repetto M, Chiara Garassino M, Loong HH, Lopez-Rios F, Mok T, Peters S, et al. NTRK gene fusion testing and management in lung cancer. Cancer Treat Rev. 2024;127:102733. (Link)
9. Kubota Y, Kawano M, Iwasaki T, Itonaga I, Kaku N, Ozaki T, et al. Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review. Jpn J Clin Oncol. 2025;55(4):313-26. (Link)

Treatment and management of TRK fusion cancer with Larotrectinib

1. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-9. (Link)
2. Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019;30(2):325-31. (Link)
3. Kummar S, Mascarenhas L, Geoerger B, Turpin B, Cox MC, Yu S, et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Journal of Clinical Oncology. 2019;37(15_suppl):6602- (Link)
4. Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, et al. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. JCO Precis Oncol. 2022;6:e2100418. (Link)
5. Tan DS-W, Drilon AE, Lin JJ, Moreno V, Kummar S, Rieke DT, et al. Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis. Journal of Clinical Oncology. 2025;43(16_suppl):8610-. (Link)
6. Hong DS, Xu R-H, Shen L, et al. Efficacy and safety of Larotrectinib as first-line treatment for patients with TRK fusion cancer: An updated analysis. Presented at the European Society of Medical Oncology 2024 Annual Meeting; September 13-17, 2024; Barcelona, Spain. (Link)
7. Brose MS; Westphalen CB; Pan X; Bernard-Gauthier V; Kurtinecz M; Guo H; Aris V; Brett NR; Majdi A; Subbiah V; Pennell NA; Kehl KL; Drilon A. Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer; JCO Precision Oncology, Volume 9 2025. (Link)
8. Tan et al., Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis. Abstract # 8610. ASCO 2025; 10.1200/JCO.2025.43.16_suppl.8610. (Link)